Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin

Abstract

T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m 2 . In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m 2 per dose.

1 . A method for treatment of T cell lymphoma comprising administering to a human patient diagnosed as having a T cell lymphoma a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. 
     
     
         2 . The method of  claim 1 , wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin. 
     
     
         3 . The method of  claim 1 , wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m 2  per dose. 
     
     
         4 . The method of  claim 3 , wherein the 10-propargyl-10-deazaaminopterin is administered weekly. 
     
     
         5 . The method of  claim 4 , wherein the 10-propargyl-10-deazaaminopterin is administered in a dose of 30 mg/m 2 . 
     
     
         6 . The method of  claim 4 , wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 150 mg,/m 2  per dose. 
     
     
         7 . The method of  claim 1 , wherein the 10-propargyl-10-deazaaminopterin is administered biweekly. 
     
     
         8 . The method of  claim 7 , wherein the 10-propargyl-10-deazaaminopterin is administered in a dosage amount of 135 to 275 mg/m 2 .